CritiTech’s Purcision™ Technology Nominated for Most Promising Drug Delivery Technology Award

Patented platform specializes in delivering 100% pure drugs directly to the site of disease Lawrence, KS— May 19, 2025 — … Continued

CritiTech PES partner NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer

Follows completion of a first-in-human dose-rising study of a single focal injection of NanoPac in patients with local prostate cancer … Continued